GE HealthCare Third Quarter 2026 Earnings Conference Call - GE HEALTHCARE TECHNOLOGIES INC

Financial Performance:

• Revenue reached $5.5 billion, up 6.2% organically, with growth across all segments and strong performance in both product (6.7%) and service (8.1%) revenues.
• Organic orders grew 4.0% in the quarter, with a trailing 12-month growth of 4.6%; book-to-bill ratio was 1.03x.
• Backlog stood at $23.7 billion, a 12% year-over-year increase, driven by broad-based demand and advanced imaging solutions.
• Adjusted EBIT margin expanded 180 basis points to 16.6%, driven by volume growth, pricing, and cost mitigation.
• Adjusted EPS was $1.34, representing a 25.1% year-over-year increase.
• Free cash flow generated was $793 million, an increase of $310 million versus the prior year, supported by reduced tariff impacts and improved operational profitability.
• The cash dividend was increased by 14%, enhancing returns to shareholders.

Guidance and Future Outlook:

• Full-year 2026 organic revenue growth guidance raised to approximately 4%.
• Full-year 2026 adjusted EBIT margin guidance raised to a range of 15.5% to 15.7%.
• Full-year 2026 adjusted EPS guidance raised to a range of $4.95 to $5.05.
• Full-year 2026 free cash flow guidance raised to in excess of $1.6 billion.
• Expected adjusted effective tax rate for 2026 is 20% to 21%, with forward exchange tailwinds to revenue of approximately 75 basis points.
• Management expressed confidence in continued momentum into 2027, citing a strong order funnel and backlog conversion, though specific 2027 guidance will be provided in February.

Business Segments and Product Lines:

• Advanced Imaging Solutions: Organic revenue grew 4.5%; margin expanded 130 basis points. Growth driven by CT, cardiovascular, and surgical innovations; received CE marking for Photonova Spectra CT and StarGuide GX spec CT.
• Pharmaceutical Diagnostics (PDX): Robust organic revenue growth of 13.8%, led by contrast media and radiopharmaceuticals (e.g., Fercato, Visimo). Segment EBIT margin expanded 50 basis points to 29.9%.
• Patient Care Solutions (PCS): Significant sequential improvement with 8.8% organic revenue growth; margin expanded 480 basis points to 12.5% (implied). Driven by operational improvements and daily management addressing prior supply challenges.
• Acquisition Strategy: Announced plans to acquire Sophie Biosciences to establish a U.S. "final mile" PET radiopharmaceutical footprint; expected to add ~1% to total annual revenue and be accretive to EBIT margin and EPS.
• Leadership Change: Jeanette Bankas stepping down as PCS CEO; Neil Sandy appointed as successor. Strategic review of the PCS business continues.

Market and Competitive Landscape:

• Demand remains strong in general imaging ultrasound, driven by staffing constraints, distributed care needs, and non-invasive imaging versatility.
• China market showing recovery with 7% growth in the quarter (largely FX-driven but with positive operational trends); team adapting tactics to evolving Volume-Based Procurement (VBP) environments.
• PDX market growing double-digits with strong adoption of Fercato for Parkinson's and cardiac imaging; transition from SPECT to PET expected to continue long-term.
• Management views the general ultrasound market as an attractive, growing global opportunity, noting competitor disruptions (e.g., recalls) but affirming GE's strong competitive position and investment in the platform.

Risks and Challenges:

• Supply Chain: Inflationary costs for memory chips and higher oil prices impacted margins; mitigated by securing multi-year agreements with technology partners for critical components.
• Macroeconomics: Persistent tariffs and inflation remain headwinds; Section 232 tariff rates are a key uncertainty, with the company preparing for potential cost increases through pricing and supply chain relocation.
• Product Dynamics: PCS fourth quarter expected to have muted growth due to comp against a product hold benefit realized in Q4 2025; not indicative of underlying market weakness.
• Competitive Pressures: Potential generic competition for OmniFay in the contrast market, though management expects new entrants to fill market gaps rather than significantly erode GE's share in a capacity-constrained environment.

Management Commentary and Tone:

• Tone was confident and positive, emphasizing "Heartbeat" operational excellence driving margin expansion and supply chain reliability.
• New CFO Bill Grogan expressed strong confidence in the team's capabilities and the "Heartbeat" methodology for driving operational rigor.
• Management highlighted the strategic "D3" approach (Devices, Drugs, Digital) and the alignment of proprietary molecules with imaging hardware as a key differentiator.
• Emphasis placed on commercial execution, including strategic pricing and standardization of product launches, to achieve profitable growth.

Analyst Questions and Answers:

• CapEx & Orders: Management confirmed capital spending remains strong with a robust order funnel; noted that large deal lumpiness can cause quarter-to-quarter volatility but the overall pipeline is resilient.
• Forcato (Radiopharma): Confirmed confidence in reaching a $500M annual revenue run rate by exiting 2028; Sophie acquisition will enhance supply chain visibility and "last mile" connectivity.
• China: Growth expected to normalize and recover; team evolving channel strategies to address VBP challenges effectively.
• Memory Chip Supply: Multi-year agreements secured to ensure "favored nation" status for supply and pricing amidst AI/data center demand.
• PCS Leadership: Leadership transition to Neil Sandy will not delay the strategic review of the PCS business; transition is seamless.
• Ultrasound: Reaffirmed commitment to investing in the general imaging ultrasound platform, citing its critical role in global markets and GE's strong brand (Logic).
• Pricing: Pricing actions are selective, focusing on differentiated value propositions; management expects 1-2% pricing headroom to be achievable in a challenging customer margin environment.
• Backlog: Backlog is at record levels; delivery schedules into 2027 and 2028 are well-secured with high installation confirmation rates.

Other Key Points:

• Regulatory Milestones: Received CE marking for Photonova Spectra CT; StarGuide GX spec CT pending FDA clearance.
• Ultrasound Innovation: Expanded platforms in cardiovascular, women's health, and general imaging to meet non-invasive demand.
• RSNA Showcase: GE Healthcare will debut significant new AI-enabled products and D3 solutions at the Radiological Society of North America (RSNA) meeting in Chicago.
• Operational Efficiency: Standardized digital support for field engineers is expected to save ~10,000 hours of field time across CT, MR, and X-ray in the U.S.
• Supply Chain Resilience: Advanced product platforming and structural cost optimization are core to the margin expansion framework.